High false-positive rate of (1,3)-β-D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies.

Abstract

Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population